DNYUZ
  • Home
  • News
    • U.S.
    • World
    • Politics
    • Opinion
    • Business
    • Crime
    • Education
    • Environment
    • Science
  • Entertainment
    • Culture
    • Music
    • Movie
    • Television
    • Theater
    • Gaming
    • Sports
  • Tech
    • Apps
    • Autos
    • Gear
    • Mobile
    • Startup
  • Lifestyle
    • Arts
    • Fashion
    • Food
    • Health
    • Travel
No Result
View All Result
DNYUZ
No Result
View All Result
Home News

Copycat Ozempic makers just lost a big court fight

April 25, 2025
in News
Copycat Ozempic makers just lost a big court fight
495
SHARES
1.4k
VIEWS
Share on FacebookShare on Twitter

 

A federal judge in Texas handed Novo Nordisk (NVO+2.41%) a big win late Thursday in its battle against cheaper versions of its blockbuster drugs Ozempic and Wegovy, rejecting a bid by compounding pharmacies to keep making the drugs while a legal challenge moves forward.

In a sealed order U.S. Judge Mark Pittman denied a request for preliminary injunction a trade group representing compounding pharmacies that would have prevented the Food and Drug Administration from taking action against its members for making knock-off versions using semaglutide, the active ingredient in the weight loss drugs.

Small-scale compounders must now immediately stop making their versions of Ozempic and Wegovy. Larger, federally licensed compounders have until May 22 to keep producing the copycats.

The popular drugs had been in short supply for some two years, which led the FDA to declare a shortage, thus allowing pharmacists to legally make compounded versions of the patented medications. Many telehealth companies also jumped into the market with compounded drugs. However, in February the FDA determined that the semaglutide shortage was over, leading to the lawsuit by Outsourcing Facilities Association.

“We are pleased the court has rejected the compounders’ attempts to undermine FDA’s data-based decision that the shortage of Wegovy® and Ozempic® is resolved,” said Steve Benz, Corporate Vice President, Legal and U.S. General Counsel, Novo Nordisk in an statement. He said that the company will continue driving legal actions forward “and escalate our efforts as necessary, while closely engaging with regulators and law enforcement.”

Compounding pharmacies make drugs tailored to individual prescriptions for a specific patient and are largely regulated by states rather than the FDA.

Eli Lilly (LLY+3.00%) has also taken aggressive legal action against compounding pharmacies, and on Wednesday filed lawsuits against four telehealth companies that offer cheaper versions of its weight loss drugs Mounjaro and Zepbound.

The post Copycat Ozempic makers just lost a big court fight appeared first on Quartz.

Share198Tweet124Share
GMC Unveils New 1,160 HP HUMMER EV Carbon Fiber Edition
News

GMC Unveils New 1,160 HP HUMMER EV Carbon Fiber Edition

by Hypebeast
May 18, 2025

Summary New for 2026, GMC adds King Crab rear-steer mode to all HUMMER EV 2X and 3X models, enhancing off-road ...

Read more
News

Montserrat Saldívar da triunfo al América sobre Chivas en feria de goles en Los Ángeles

May 18, 2025
News

PGA Championship: Rakes, snakes, an ace and Vegas reigns supreme in second round

May 18, 2025
News

Times Sq. Sculpture Prompts Racist Backlash. To Some, That’s the Point.

May 18, 2025
News

‘She Was Trying to Tie Her Partner’s Bow Tie but Kept Failing’

May 18, 2025
New Jersey, State of Constant Motion, Learns to Live With Immobility

New Jersey, State of Constant Motion, Learns to Live With Immobility

May 18, 2025
Scarlett Johansson Gets Her Apology on Saturday Night Live Season Finale

Scarlett Johansson Gets Her Apology on Saturday Night Live Season Finale

May 18, 2025
As Europe Speeds By on Rail, America Is Stuck in Traffic

Trump Isn’t the First Politician to Sell the Office

May 18, 2025

Copyright © 2025.

No Result
View All Result
  • Home
  • News
    • U.S.
    • World
    • Politics
    • Opinion
    • Business
    • Crime
    • Education
    • Environment
    • Science
  • Entertainment
    • Culture
    • Gaming
    • Music
    • Movie
    • Sports
    • Television
    • Theater
  • Tech
    • Apps
    • Autos
    • Gear
    • Mobile
    • Startup
  • Lifestyle
    • Arts
    • Fashion
    • Food
    • Health
    • Travel

Copyright © 2025.